PGC1α Plays a Critical Role in TWEAK-Induced Cardiac Dysfunction

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Shi, Jianru ^a   Jiang, Bingbing ^a   Qiu, Yiling ^a   Guan, Jian ^a   Jain, Mohit ^a   Cao, Xin ^a   Bauer, Michael ^a   Su, Lihe ^b   Burkly, Linda C ^b   Leone, Teresa C ^c   Kelly, Daniel P ^c   Liao, Ronglih ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BIOGEN   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART CONTRACTION; HEART DISEASE; MALE; MITOCHONDRION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ECHOCARDIOGRAPHY; FIBROBLAST GROWTH FACTORS; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NF-KAPPA B; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANS-ACTIVATORS; TUMOR NECROSIS FACTORS;

ADENOVIRIDAE; MUS;

EID: 84872471216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054054     Document Type: Article

References (35)

1. Burkly LC, Michaelson JS, Zheng TS, (2011) TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 244: 99-114.
2. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, et al. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-32410.
3. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, et al. (2006) Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 176: 1889-1898.
4. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS, (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40: 1-16.
5. Winkles JA, (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425.
6. Weinberg JM, (2011) TWEAK-Fn14 as a mediator of acute kidney injury. Kidney Int 79: 151-153.
7. Yepes M, Winkles JA, (2006) Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases. Drug News Perspect 19: 589-595.
8. Kumar A, Bhatnagar S, Paul PK, (2012) TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 15: 233-239.
9. Jain M, Jakubowski A, Cui L, Shi J, Su L, et al. (2009) A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119: 2058-2068.
10. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, et al. (2012) Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 211: 322-326.
11. Finck BN, Kelly DP, (2007) Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115: 2540-2548.
12. Rowe GC, Jiang A, Arany Z, (2010) PGC-1 coactivators in cardiac development and disease. Circ Res 107: 825-838.
13. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, et al. (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25: 5826-5839.
14. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, et al. (2005) TWEAK induces liver progenitor cell proliferation. J Clin Invest 115: 2330-2340.
15. Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, et al. (2011) Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ Res 108: 908-916.
16. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, et al. (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107: 4188-4193.
17. Liao R, Jain M, (2007) Isolation, culture, and functional analysis of adult mouse cardiomyocytes. Methods Mol Med 139: 251-262.
18. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, et al. (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847-856.
19. Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL, (2010) Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol 25: 329-334.
20. Stanley WC, Recchia FA, Lopaschuk GD, (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129.
21. Schilling J, Kelly DP, (2011) The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol 51: 578-583.
22. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA, (2003) The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 371: 395-403.
23. Liang H, Ward WF, (2006) PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ 30: 145-151.
24. Finck BN, Kelly DP, (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622.
25. Puigserver P, Spiegelman BM, (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90.
26. Arany Z, He H, Lin J, Hoyer K, Handschin C, et al. (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271.
27. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, et al. (2004) Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94: 525-533.
28. Wiley SR, Winkles JA, (2003) TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14: 241-249.
29. Arch RH, Gedrich RW, Thompson CB, (1998) Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes Dev 12: 2821-2830.
30. Enwere EK, Holbrook J, Lejmi-Mrad R, Vineham J, Timusk K, et al. (2012) TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF-kappaB Signaling Pathway. Sci Signal 5: ra75.
31. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, et al. (2011) The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 22: 1315-1325.
32. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, et al. (2010) Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 185: 1593-1605.
33. Shih VF, Tsui R, Caldwell A, Hoffmann A, (2011) A single NFkappaB system for both canonical and non-canonical signaling. Cell Res 21: 86-102.
34. Brown SA, Ghosh A, Winkles JA, (2010) Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 285: 17432-17441.
35. Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, et al. (2010) The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res 87: 449-458.